United Therapeutics (UTHR) Form 4 Filings

UNITED THERAPEUTICS Corp director Nilda Mesa reported the vesting and conversion of equity awards. On July 9, 2026, 650 restricted stock units vested and were converted on a one-for-one basis into 650 shares of common stock. Following this compensation-related transaction, Mesa directly holds 5,678 shares of common stock.

UNITED THERAPEUTICS Corp director Judy D. Olian reported the vesting of equity awards. On July 9, 2026, 1,310 Restricted Stock Units vested and converted on a one-for-one basis into 1,310 shares of common stock at an exercise price of $0.00 per share. Following this conversion, Olian holds 5,555 shares of common stock directly, and the reported Restricted Stock Unit position is reduced to zero. The transactions reflect compensation-related vesting, not an open‑market purchase or sale.

UNITED THERAPEUTICS Corp director Christopher Patusky reported a compensation-related equity event. On July 9, 2026, 650 Restricted Stock Units vested and converted on a one-for-one basis into 650 shares of common stock at a stated price of $0.00 per share. Following this vesting, he held 2,140 shares of common stock directly, in addition to 1,100 shares held indirectly by trust. The RSU award involved in this transaction was fully converted, with no remaining units from that grant.

UNITED THERAPEUTICS Corp director Louis W. Sullivan reported the vesting of 650 restricted stock units on July 9, 2026, which converted on a one-for-one basis into 650 shares of common stock. Following the transaction, he holds 2,983 common shares directly and 867 common shares indirectly through a trust over which he has sole investment and voting power.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of transactions in Common Stock on July 10, 2026. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of Common Stock in multiple open-market trades at prices reported between $540.37 and $553.47 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she holds 40,513 shares of Common Stock directly, plus additional indirect holdings in family trusts and stock options on 349,192 shares held indirectly through a family trust.

UNITED THERAPEUTICS Corp director Jan Malcolm received 650 shares of common stock on July 9, 2026 upon vesting of restricted stock units that converted one-for-one into common shares. On July 10, 2026, Malcolm executed an open-market sale of 325 common shares at $550.59 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Malcolm directly holds 450 common shares.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in common stock on July 9, 2026. She exercised 9,500 stock options at $135.42 per share and sold the resulting 9,500 shares in multiple open-market trades at weighted average prices around $548–$556, all pursuant to a pre-arranged Rule 10b5-1 trading plan. After these trades, she held 40,513 shares directly, along with additional indirect holdings through family trusts and stock options on 349,192 shares held in a family trust, as well as a plan that may cover the exercise of up to 1,734,410 stock options expiring on March 15, 2027.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a planned transaction. On 2026-07-08, she exercised options to acquire 9,500 shares of common stock at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades at weighted-average prices in the mid-$550 range. The filing states these option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly and continues to have additional indirect holdings through family trusts and her spouse, as well as stock options held indirectly on 349,192 underlying shares expiring on March 15, 2027.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in the company’s common stock. On July 7, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the mid-$550s to low-$560s.

A footnote states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Following the transactions, Rothblatt directly holds 40,513 common shares and has additional indirect holdings through family trusts and a spouse, as well as stock options on 349,192 underlying shares held indirectly via a family trust.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 common shares in open-market trades around $548–$554 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Following these transactions, she directly holds 40,513 common shares and also has substantial indirect interests through family trusts, including stock options on 349,192 underlying shares at an exercise price of $135.42 expiring on March 15, 2027.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a mix of option exercises and share sales in company stock. She exercised 9,500 stock options for common shares at an exercise price of $135.42 per share and sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $547.45 and $558.18. Following these transactions, she directly held 40,513 shares of common stock. The filing states that the option exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring on March 15, 2027, and is scheduled to continue until the earlier of that full exercise or December 31, 2026. In addition to direct holdings, Rothblatt has indirect ownership interests through family trusts and a spouse account, and retains stock options held in a family trust covering 349,192 underlying common shares at an exercise price of $135.42 per share expiring on March 15, 2027.

UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised 8,300 stock options and sold 8,300 common shares in pre-planned trades. On the transactions date, he exercised options at a strike price of $146.03 per share and sold the resulting shares in multiple open-market transactions at weighted average prices generally around the mid-$500s per share. The trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, indicating they were scheduled in advance. Following these transactions, Mahon directly owns 45,172 shares of UNITED THERAPEUTICS common stock.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported option exercises and share sales in UTHR stock. On July 1, 2026, she exercised 9,500 stock options at $135.42 per share and received the same number of common shares.

Those 9,500 shares were then sold in a series of open-market transactions at weighted-average prices generally around the mid-$540s per share, with individual trades executed within price ranges from $537.26 to $549.65. Following these transactions, she held 40,513 common shares directly, along with additional indirect holdings through family trusts and her spouse.

The filing notes that this exercise and sale activity was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026, and a family trust continues to hold 349,192 stock options with a $135.42 exercise price.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. On June 30, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring the same number of common shares.

The filing shows open‑market sales of 9,500 common shares that day in multiple trades at weighted average prices generally between about $535.93 and $549.44. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until up to 1,734,410 stock options are exercised or until December 31, 2026, whichever occurs first.

After the reported transactions, Rothblatt directly holds 40,513 common shares. She also has additional indirect holdings of common stock and stock options through various family trusts and her spouse’s account, as described in the filing’s ownership footnotes.

United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share, then sold 9,500 shares in multiple open‑market transactions at prices reported between $539.9783 and $548.9605 per share. These transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following the trades, Rothblatt directly holds 40,513 shares of common stock and continues to have substantial indirect holdings through family trusts, as well as stock options held indirectly covering 349,192 underlying shares that expire on March 15, 2027.

United Therapeutics chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold 9,500 shares of common stock of United Therapeutics on June 26, 2026. The options carried a $135.42 exercise price and were exercised and sold under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

The Form 4 shows multiple open-market sale transactions at prices reported around the low to mid $540s to $550s per share. Following these transactions, Rothblatt held 49,373 common shares directly, along with additional indirect holdings through family trusts and her spouse.

The filing also reports a large remaining stock option position held indirectly via a family trust, covering 349,192 underlying shares at a $135.42 exercise price and expiring on March 15, 2027. The footnotes emphasize that these transactions are part of a continuing 10b5-1 plan that may run until the earlier of exercising 1,734,410 options or December 31, 2026.

United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported option exercises and share sales in United Therapeutics common stock. She exercised stock options covering 9,500 shares at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades.

According to the footnotes, these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. The reported sales were executed in multiple trades at weighted average prices between $543.12 and $555.31 per share.

In addition to direct holdings, various family trusts and a spouse account hold United Therapeutics common stock and stock options, including a family trust stock option position tied to 349,192 underlying shares at a $135.42 exercise price expiring on March 15, 2027.

United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned option exercise and share sales. On June 24, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $135.4200 per share and sold 9,500 shares in multiple open-market transactions.

The sales, coded "S," occurred at weighted-average prices between roughly $545.46 and $553.48, as detailed in the footnotes. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Separate entries show additional indirect holdings and stock options held through family trusts and by a spouse.

United Therapeutics Chairperson and CEO Martine Rothblatt reported exercising stock options and selling shares of common stock in a planned transaction. On June 23, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices around $540–$546 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares of common stock directly, additional indirect common stock positions through various family trusts and a spouse account, and stock options on 349,192 underlying shares held indirectly through a family trust.

United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported option exercises and related share sales in a Form 4. On June 22, 2026, she exercised stock options to acquire 9,500 shares of common stock at exercise prices of $146.03 and $135.42 per share, then sold 9,500 shares in multiple open-market transactions at prices generally around the mid‑$530s per share, all under a pre-arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 49,781 shares of common stock and has an indirect stock option position covering 349,192 underlying shares expiring on March 15, 2027. Additional common shares and options are held indirectly through various family trusts and by her spouse as described in the filing.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 8,750 shares of common stock at an exercise price of $146.03 per share and sold 8,750 shares in open‑market transactions on June 22, 2026. The sales were executed at weighted average prices around the mid‑$530s to low‑$540s per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly holds 18,876 shares of UNITED THERAPEUTICS common stock.

United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $146.03 per share and sold 10,000 shares in multiple open-market trades at prices between $533.25 and $549.17, all pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 shares of common stock and held 8,750 stock options.

United Therapeutics Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold the same 9,500 shares in multiple open-market transactions on June 18, 2026.

The reported sales included trades such as 2,793 shares at $539.62 per share and 160 shares at $552.72 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring on March 15, 2027 or runs until December 31, 2026, whichever comes first.

After these transactions, Rothblatt holds 49,533 shares of common stock directly, along with additional indirect holdings through various family trusts and her spouse.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised and sold company stock in a planned transaction. On June 18, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting 8,300 common shares in multiple open-market trades under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. The sales occurred at weighted-average prices generally in the mid-$530s to mid-$550s per share, as detailed in the trade price ranges.

United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 17, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the $548–$556 per share range.

According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of exercising up to 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists additional indirect holdings in United Therapeutics common stock through various family trusts and the reporting person’s spouse.

United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 16, 2026, she exercised 9,500 stock options at $146.03 per share and acquired the same number of common shares.

Those 9,500 shares were then sold in multiple open-market trades at prices between $545.18 and $554.63 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these trades, she held 40,513 shares of common stock directly, plus additional indirect holdings through various family trusts and a small position of 166 shares held by her spouse.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting 9,500 shares of common stock. The options were exercised at an exercise price of $146.03 per share, and the shares were sold in multiple open-market transactions at prices generally in the mid-$540s per share.

According to the filing, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of the exercise of 1,734,410 stock options, all expiring on March 15, 2027, or December 31, 2026. The filing also reports additional indirect holdings in family trusts and by the CEO’s spouse.

United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales. On June 15, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share and converted those options into stock.

On the same date, he sold 10,000 shares of United Therapeutics common stock in multiple open-market transactions, at weighted average prices generally in the low-to-mid $500s per share, as detailed by price ranges in the footnotes. After these transactions, he directly owned 18,876 shares of common stock. The filing states that the option exercise and subsequent sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.

United Therapeutics Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share on June 12, 2026 and sold the resulting 9,500 common shares in multiple trades at weighted prices between $536.82 and $546.11, under a Rule 10b5-1 trading plan adopted November 7, 2025. After these transactions, she holds 40,513 shares directly and 628,049 shares indirectly through family trusts.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share, then sold 10,000 shares in multiple open-market trades on the same day under a Rule 10b5-1 trading plan. Following these transactions, he holds 18,876 shares of common stock directly.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, acquiring the same number of common shares.

That day, she sold 9,500 common shares in multiple open‑market trades at weighted average prices around $542–$552 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she holds 49,931 common shares directly, with additional shares held indirectly through family trusts and by her spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported option-related trades in company common stock. She exercised 9,500 stock options at an exercise price of $146.03 per share and related open-market sales covered the same number of shares, resulting in a net sale of 9,500 shares according to the filing summary.

The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and 59,910 stock options, and also has additional indirect holdings through various family trusts and a spouse account.

United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On June 9, 2026, she exercised 9,500 stock options for common stock at an exercise price of $146.03 per share, then sold 9,500 common shares in a series of open‑market transactions at weighted average prices around $545–$553 per share.

The filing notes these transactions were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these trades, the report shows 50,013 common shares held directly, along with additional indirect holdings through various family trusts and by a spouse, and 69,410 stock options remaining from the reported option grant.

United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock. On June 8, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share to acquire 10,000 shares.

That same day, he sold 10,000 common shares in a series of open‑market transactions at weighted average prices ranging from the mid‑$540s to low‑$550s per share. According to the filing, these trades were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025.

Following these transactions, Edgemond directly holds 18,876 shares of United Therapeutics common stock, and the filing shows no remaining derivative (stock option) position tied to this grant.

UNITED THERAPEUTICS (UTHR) Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 8, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at prices generally around $545–$551 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, she held 40,513 shares of common stock directly, in addition to several indirect holdings through family trusts and shares held by her spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sale transaction in company stock. On June 5, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and received an equal number of common shares.

The same day, she sold 9,500 shares of common stock in open-market trades, with footnotes stating prices ranged from $545.345 to $550.58 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 40,513 shares of common stock and indirectly holds additional shares through family trusts and a spouse account, while retaining 88,410 stock options expiring on March 15, 2027.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a combination of option exercise and share sales in company stock. He exercised stock options covering 10,000 shares of Common Stock at a strike price of $117.76 per share and, on the same date, executed open-market sales totaling 10,000 shares of Common Stock.

The sales were broken into multiple trades at weighted average prices generally in the mid‑$540 range per share, as detailed in the filing. According to the transaction summary, these moves result in a net disposition of 10,000 shares. The filing notes that the option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5-1 trading plan entered into by Edgemond on October 31, 2025.

United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share, then sold the same 9,500 shares in multiple open-market trades at weighted average prices in the mid-$540 range.

The activity occurred on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists indirect holdings in common stock through various family trusts and the reporting person’s spouse.

UNITED THERAPEUTICS Corp executive vice president and general counsel Paul A. Mahon reported an exercise-and-sell transaction in company stock. He exercised stock options covering 8,300 shares of common stock at $146.03 per share and, on the same date, sold 8,300 shares in a series of open-market trades at prices generally around $543–$549 per share. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan that Mahon entered into on August 11, 2025. Following these transactions, he directly holds 45,172 shares of UNITED THERAPEUTICS common stock.

United Therapeutics Chairperson & CEO Martine Rothblatt reported a same-day option exercise and share sale in United Therapeutics Corp. common stock. She exercised 9,500 stock options at $146.03 per share and sold 9,500 shares in multiple open‑market trades, at prices generally in the mid‑$540s to low‑$550s per share, under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she directly owned 40,513 common shares and also reported additional indirect holdings through various family trusts and her spouse.

United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 2, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in open-market transactions at prices disclosed in ranges between $535.16 and $543.40 per share under a pre-arranged Rule 10b5-1 trading plan.

Following these transactions, Rothblatt owns 40,513 shares of United Therapeutics common stock directly. In addition, family trusts and a spouse account hold indirect positions, including trusts with 324,443, 249,108, 45,596, and 8,902 shares and a spouse-held position of 166 shares.

The footnotes state that the trading plan, adopted on November 7, 2025, will continue until the earlier of the exercise of 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares under a pre-arranged plan. On June 1, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and received 9,500 shares of common stock.

That same day, she sold 9,500 common shares in multiple open-market transactions at prices generally in the $544–$555 range, as shown by individual trades such as 2,213 shares at $546.2054 per share. These trades were executed pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until either the exercise of up to 1,734,410 stock options that expire on March 17, 2027, or December 31, 2026, whichever occurs first.

After these transactions, Rothblatt directly held 40,513 shares of common stock and 126,410 stock options, and also had indirect ownership of additional common shares through various family trusts and a small position held by her spouse.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 10,000 shares of Common Stock at an exercise price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market trades at weighted average prices generally around the mid‑$540s to mid‑$550s per share. The filing states that this option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5‑1 trading plan. Following these transactions, Edgemond directly owns 18,876 shares of UNITED THERAPEUTICS Common Stock.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt sold 1,500 shares of common stock in an open‑market transaction. The sale occurred on May 26, 2026 at a weighted average price of $575.9649 per share, leaving her with 43,153 shares directly held afterward.

The shares sold were acquired through an option exercise and the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. This Form 4/A amendment corrects the transaction code from a purchase to the proper sale code while keeping the disposition and share counts consistent.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 29, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open‑market trades at weighted average prices in the mid‑$550s, all pursuant to a pre‑arranged 10b5‑1 trading plan. Following these transactions, she directly holds 40,513 shares of common stock and 135,910 stock options, in addition to indirect holdings through family trusts and her spouse.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at a price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market transactions.

The reported sales occurred at weighted average prices ranging from approximately $561.48 to $571.48 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, Edgemond directly holds 18,876 shares of Common Stock and 50,000 stock options.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions around $561–$572 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to run until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. On May 27, 2026, she exercised stock options to acquire 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in open-market trades at prices mostly around the high $570s per share.

After these transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through family trusts and her spouse. The filing notes that the option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised 10,000 stock options for Common Stock at an exercise price of $117.76 per share, then sold 10,000 shares of Common Stock in multiple open-market sales on May 26, 2026.

The sales were executed in numerous trades at weighted average prices within ranges from about $558.79 to $578.53 per share and were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 shares of Common Stock and continues to hold stock options.